All In Biotech

NDA 018956 · Ge Healthcare

Omnipaque 140

Iohexol · Injection, Injection, Oral, Rectal, Oral, Injection, Oral, Urethral · Radiographic Contrast Agent

Novel

Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Dec 26, 1985

Approved uses

14

Original approval plus efficacy supplements

Registered trials

74

5 Phase 3, 10 recruiting

FAERS reports

8,472

6,838 serious, 503 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of OMNIPAQUE of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema [see Warnings and Precautions (5.1) ]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 and 350 mg IODINE/mL Use only the iodine concentrations and presentations recommended for intrathecal procedures. Intrathecal administration of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures,...

What it is approved for

From the label in effect Apr 28, 2026.

OMNIPAQUE is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures in adults and pediatric patients. ( 1 ) 1.1 Intrathecal Procedures ‡ OMNIPAQUE is indicated for: Myelography and computerized tomography (CT) myelography (lumbar, thoracic, cervical, total columnar) in adults and pediatric patients aged 2 weeks and older CT cisternography in adults and pediatric patients aged 2 weeks and older 1.2 Intra-arterial Procedures ‡ OMNIPAQUE is indicated for: Cardiac ventriculography in adults and pediatric patients Aortography including studies of aorta and its branches in adults and pediatric patients Selective coronary arteriography in adults Cerebral arteriography in adults Peripheral arteriography in adults Intra-arterial digital subtraction angiography (IA-DSA) of the head, neck, abdominal, renal, and peripheral vessels in adults Pulmonary angiography in pediatric patients 1.3 Intravenous Procedures ‡ OMNIPAQUE is indicated for: Excretory urography in adults and pediatric patients CT of the head and body in adults and pediatric patients Peripheral venography (phlebography) in adults Intravenous digital subtraction angiography (IV-DSA) of the head, neck, abdominal, renal, and peripheral vessels in adults 1.4 Oral or Rectal Procedures ‡ OMNIPAQUE is indicated for: Radiographic examination of the gastrointestinal (GI) tract by oral administration in adult patients and by oral or rectal administration in pediatric patients CT of the abdomen and pelvis by oral administration in adult and pediatric patients, in conjunction with intravenous administration of OMNIPAQUE 1.5 Intraarticular Procedures ‡ OMNIPAQUE is indicated for: Arthrography in adults 1.6 Body Cavity Procedures ‡...

Mechanism: The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohexol provides time-dependent image contrast which may assist in visualizing body structures.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 13, 1993 Supplement 28 · Efficacy Review
  • Nov 30, 1989 Supplement 26 · Efficacy
  • Jul 28, 1989 Supplement 22 · Efficacy
  • Jul 28, 1989 Supplement 23 · Efficacy
  • Jun 30, 1989 Supplement 20 · Efficacy
  • Jun 30, 1989 Supplement 21 · Efficacy
  • Mar 31, 1989 Supplement 18 · Efficacy
  • Nov 30, 1988 Supplement 17 · Efficacy
  • Jul 29, 1988 Supplement 14 · Efficacy
  • May 24, 1988 Supplement 15 · Efficacy
  • Feb 1, 1988 Supplement 12 · Efficacy
  • May 12, 1987 Supplement 9 · Efficacy
  • Nov 26, 1986 Supplement 1 · Efficacy
  • Dec 26, 1985 Original approval · Type 1 - New Molecular Entity
9 products under this application
  • OMNIPAQUE 140 · IOHEXOL 30.2% · INJECTABLE, INJECTION · Prescription
  • OMNIPAQUE 300 · IOHEXOL 64.7% · SOLUTION, INJECTION, ORAL, RECTAL · Prescription · TE AP
  • OMNIPAQUE 180 · IOHEXOL 38.8% · SOLUTION, INJECTION, ORAL, RECTAL · Prescription
  • OMNIPAQUE 9 · IOHEXOL 1.9% · SOLUTION, ORAL · Prescription
  • OMNIPAQUE 210 · IOHEXOL 45.3% · INJECTABLE, INJECTION · Discontinued
  • OMNIPAQUE 350 · IOHEXOL 75.5% · SOLUTION, INJECTION, ORAL · Prescription · TE AP
  • OMNIPAQUE 240 · IOHEXOL 51.8% · SOLUTION, INJECTION, ORAL, RECTAL · Prescription
  • OMNIPAQUE 12 · IOHEXOL 2.6% · SOLUTION, ORAL · Prescription
  • OMNIPAQUE 70 · IOHEXOL 15.1% · SOLUTION, URETHRAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Iohexol" as an intervention, any sponsor and status, largest first.

All 74 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urticaria1,021
  • pruritus929
  • dyspnoea799
  • sneezing630
  • erythema586
  • nausea538
  • vomiting494
  • rash430
  • chills360
  • cough338
  • anaphylactic reaction322
  • acute kidney injury299

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200510
20065
20077
200811
20096
201013
201117
2012175
2013370
2014699
2015601
2016578
2017697
2018576
2019550
2020577
2021489
2022491
2023542
2024617
2025778
2026656

Recalls

3 FDA enforcement reports for this application.

  • Mar 24, 2026 · Class II · Ongoing

    Presence of particulate matter

  • Mar 24, 2026 · Class II · Ongoing

    Presence of particulate matter

  • Oct 29, 2018 · Class II · Terminated

    Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 518 on PubMed

Sponsor: Ge Healthcare · Also marketed as Omnipaque 300, Omnipaque 180, Omnipaque 9, Omnipaque 210, Omnipaque 350

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.